Kim Jong Joseph 4
4 · INOVIO PHARMACEUTICALS, INC. · Filed Mar 14, 2022
Insider Transaction Report
Form 4
Kim Jong Joseph
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2022-03-11+139,387→ 1,462,325 total - Tax Payment
Common Stock
[F2]2022-03-11$3.22/sh−39,698$127,828→ 1,422,627 total - Exercise/Conversion
Restricted Stock Unit
[F1]2022-03-11−139,387→ 139,386 total→ Common Stock (139,387 underlying)
Holdings
- 816,527(indirect: By Partnership)
Common Stock
- 33,563(indirect: By Daughter: EK)
Common Stock
- 33,775(indirect: By Son: JK1)
Common Stock
- 5,975(indirect: By Spouse)
Common Stock
- 33,533(indirect: By Son: JK2)
Common Stock
Footnotes (2)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares vested on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
- [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein.
Signature
/s/ Jong Joseph Kim|2022-03-14